Trial Profile
A multicenter, double-blind, placebo-controlled, parallel-group study of ONO-5163 in patients with secondary hyperparathyroidism on hemodialysis (ONO-5163-03)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Jul 2022
Price :
$35
*
At a glance
- Drugs Etelcalcetide (Primary)
- Indications Secondary hyperparathyroidism
- Focus Therapeutic Use
- Sponsors Ono Pharmaceutical
- 30 Jul 2020 Results of meta-analysis of four studies (NCT01785849, NCT01254565, JapicCTI142664 & JapicCTI121978) assessing efficacy and safety of etelcalcetide for the treatment of secondary hyperparathyroidism (SHPT) in patients receiving hemodialysis, published in the Clinical Nephrology.
- 05 Jan 2017 Results published in the Nephrology Dialysis Transplantation
- 30 May 2016 New trial record